Aventis Expects Existing Drugs To Fuel Growth
Article Abstract:
Strasbourg, France-based Aventis S.A., which was fomed in 1999 through the merger of Hoechst AG and Rhone Poulenc SA, has reported a loss of $147 million in Euro dollars for 2000. Aventis expects to increase its earnings through sales of key drugs, such as the Allegra allergy medication.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Aventis's core-business profit jumped 31% in third quarter
Article Abstract:
Aventis S.A. announced net income at its core life-sciences division increased 31% in the third quarter, not including one-time restructuring charges, and revised its full-year growth forecast for net income from 30% to 40%.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Aventis will fund U.S. repurchase of modified corn
Article Abstract:
Aventis S.A. will finance a U.S. multimillion-dollar repurchase of StarLink, the company's genetically modified corn.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Akzo's net falls 7% but beats estimates. Akzo Nobel posts a 30% profit rise for first-quarter. Akzo likely to post a modest increase in 1999 net profit
- Abstracts: Goldman Sachs's net income jumps 31%. Goldman's profit jumps by half on trading success
- Abstracts: Paris signals softening on Aerospatiale. A virtual conquest of Europe. Carrefour catches on to the Internet
- Abstracts: Mmmuffins seeking upscale diners. McDonald's serves it up to Cossette. Veering off from the mainstream
- Abstracts: A fixed interval due-date scheduling problem with earliness and due-date costs. Commonality in product design: cost saving, valuation change and cannibalization